Aeolus Pharmaceuticals, Inc.  

(Public, OTCMKTS:AOLS)   Watch this stock  
Find more results for OTC:AOLS
0.192
+0.003 (1.58%)
Feb 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.19 - 0.19
52 week 0.10 - 0.50
Open 0.19
Vol / Avg. 1,714.00/24,632.00
Mkt cap 29.99M
P/E     -
Div/yield     -
EPS -0.04
Shares 152.09M
Beta 1.81
Inst. own 73%
Feb 14, 2017
Q1 2017 Aeolus Pharmaceuticals Inc Earnings Release (Estimated)
Dec 21, 2016
Q4 2016 Aeolus Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -1309.64% -171.39%
Operating margin -1309.64% -157.66%
EBITD margin - -157.66%
Return on average assets -127.93% -119.72%
Return on average equity -163.60% -515.48%
Employees 4 -
CDP Score - -

Address

26361 Crown Valley Pkwy Ste 150
MISSION VIEJO, CA 92691-7324
United States - Map
+1-949-4819825 (Phone)
+1-919-5588686 (Fax)

Website links

Description

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.

Officers and directors

David C. Cavalier Chairman of the Board, Interim Chief Financial Officer
Age: 45
John L. McManus President, Chief Executive Officer
Age: 50
John M. Clerici Independent Director
Age: 44
John M. Farah Jr., Ph.D. Independent Director
Age: 62
Mitchell D. Kaye J.D. Independent Director
Age: 46
Amit Kumar Ph.D. Independent Director
Age: 52
Chris A. Rallis Independent Director
Age: 61